Recurrent Gastrointestinal Carcinoid Tumor Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028801 (Recurrent Gastrointestinal Carcinoid Tumor)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00055809Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid TumorsTreatment